Olanzapine Articles
Eli Lilly falls as 2012 forecasts disappoint
6 January 2012
New Zealand in deal with Mylan to list generic olanzapine and apply reference pricing across brands of the antipsychotic
2 November 2010
In USA, Lundbeck wins Federal Trade Commission case over NeoProfen; Lilly wins Court action on Zyprexa
13 September 2010
Eli Lilly gets bonus with FDA’s Zyprexa Relprew approval
4 January 2010
Eli Lilly outlines innovation strategy, sets 2010 financial guidance, but disappoints Wall Street
11 December 2009
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
Atypical antipsychotics cause significant weight gain in children and young adults, JAMA study reports
28 October 2009
Eli Lilly 3rd quarter 2009 beats forecasts, raises guidance
22 October 2009
Public Citizen’s HRG slams Pfizer’s $2.3 billion settlement as not enough to deter bad behaviour by Pharma
9 September 2009
Lilly's 1st-qtr profit jumps 23.6% to $1.31B
29 April 2009
Daiichi/Lilly's Efient gets first world launch in UK - first new antiplatelet drug in a decade
9 April 2009
Lilly's Symbyax is first FDA approved TRD drug
30 March 2009
Stock Commentary - New York week to Mar 2, 2009
9 March 2009
"30,000" fake drug packs given to NHS patients
9 February 2009
Corlux mitigates Risperdal weight gain
9 February 2009
Lilly swings to loss on ImClone acquisition
9 February 2009
Lilly's $1.4B Zyprexa settlement confirmed
19 January 2009
Prasugrel gets nod from CHMP
12 January 2009
Lilly swings into loss in 3rd qtr on legal costs
3 November 2008
Lilly to take $1.4B charge to resolve past practices
27 October 2008
Lilly/Daiichi reassure investors on prasugrel
27 October 2008
Lilly pays $62M to end Zyprexa investigation
13 October 2008
SPD Minister attacks Germany's drugmakers
29 September 2008
Strong maintenance data for olanzapine LAI
15 September 2008
Vanda's shares halve on US iloperidone setback
4 August 2008
Lilly's 2nd-qtr rise hides coming challenges
4 August 2008
Fed judge urges Lilly to settle multi-billion suit
21 July 2008
Lilly has good 1Q sales but still disappoints
28 April 2008
Lilly settles Zyprexa Alaska case for $15M
31 March 2008
Promotional spending on atypical antipsychotice analyzed
17 March 2008
Zyprexa LAI gets FDA non-approvable letter
10 March 2008
Japan stock market week to Feb 25, 2008
3 March 2008
FDA c'tee recommends Zyprexa LAI approval
18 February 2008
Lilly's 4th qtr recovers from Zyprexa settlement
4 February 2008
US Congress to re-open drug import debate
28 January 2008
Daiichi Sankyo and Eli Lilly submit NDA to US FDA for prasugrel; to be sold as Effient
14 January 2008
German generics see drug majors cut prices
14 January 2008
Japan stock market week to Dec 3, 2007
10 December 2007
Call for EU review of parallel trade by EAASM
26 November 2007
Actavis' olanzapine launched in Germany
19 November 2007
Eli lilly sees 3rd qtr net income climb 6% as sales jump 19% to $4.6B, raises full-year guidance
29 October 2007
Review of the annual meeting of the ECNP
22 October 2007
Lilly adds warnings to Zyprexa and Symbyax
15 October 2007
UPDATE: China's fake Rx drug factories exposed, imitation Viagra "would give overdose"
1 October 2007
Patent expiries will reduce bipolar drug market $400M
1 October 2007
Janssen and AstraZeneca drugs now lead antipsychotics
24 September 2007
Seroquel as effective as olanzapine in mania
3 September 2007
Lilly's 2nd-qtr 20% sales hike beats estimates
30 July 2007
Barr drops challenge on Lilly's US Zyprexa patent
18 June 2007
Lilly to appeal generic Zyprexa rulings
18 June 2007
Strong Ph III data for Organon's asenapine
4 June 2007
Fake parallel trade drug hits UK, product recall
4 June 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
Grassley seeks Zyprexa safety and selling data
16 April 2007
Eli Lilly Japan's 2006 sales up 7% to $700M
2 April 2007
Lilly to buy Hypnion for access to drugs
12 March 2007
Waxman investigates marketing practices
12 March 2007
Lilly granted injunction on document leaks
26 February 2007
Lilly's income down 81%, but shares up 1.5%
12 February 2007
Eli Lilly settles further Zyprexa law suits
15 January 2007
Good patent news for Lilly, Pfizer and Sanofi-Aventis
8 January 2007
Lilly accused of off-label Zyprexa promotion
22 December 2006
Lilly reiterates 2006/07 guidance, disappoints
18 December 2006
Lilly maintains cost-effectiveness of Zyprexa
11 December 2006
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
Poland's drug market up 4% in first 7 months
6 November 2006
Lilly's 3rd-qtr 2006 profit rises 10% on Zyprexa
30 October 2006
Eli Lilly PAP approved, patients hit by Part D loophole
9 October 2006
Lilly swings to 2nd-qtr 2006 EPS of $0.76
31 July 2006
Eli Lilly profit up 6% in 1st-qtr 2006
1 May 2006
Drug studies "biased" towards sponsors
24 April 2006
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
